NR 566 / NR566 Advanced Pharmacology Care of the
Family Midterm Review Actual 2025/2026 with Detailed
Rationales | 100% Verified | Pass Guaranteed – A+
Graded
SECTION 1: Pharmacokinetics & Pharmacodynamics (15 questions)
Q1: A patient with renal impairment is prescribed a drug primarily eliminated by the
kidneys. Which pharmacokinetic parameter is most affected?
A. Absorption
B. Distribution
C. Metabolism
D. Elimination [CORRECT]
Correct Answer: D
Rationale: Correct because renal impairment primarily reduces drug elimination,
leading to accumulation and potential toxicity; dose adjustment is essential for
renally cleared medications.
Q2: A patient taking warfarin also starts phenytoin. The INR decreases. Which
pharmacokinetic interaction occurred?
A. Phenytoin inhibits warfarin absorption
B. Phenytoin induces hepatic cytochrome P450 enzymes, increasing warfarin
metabolism [CORRECT]
C. Phenytoin displaces warfarin from plasma proteins
D. Phenytoin decreases warfarin renal excretion
Correct Answer: B
Rationale: Correct because phenytoin is a potent CYP450 enzyme inducer that
accelerates warfarin metabolism, reducing its anticoagulant effect and requiring INR
monitoring with dose adjustment.
Q3: Which factor most increases the volume of distribution for lipophilic drugs?
A. Increased plasma protein binding
B. Decreased body fat
,C. Increased adipose tissue [CORRECT]
D. Decreased cardiac output
Correct Answer: C
Rationale: Correct because lipophilic drugs distribute extensively into adipose tissue;
increased body fat expands the apparent volume of distribution and may prolong
drug half-life.
Q4: A drug with a narrow therapeutic index requires which nursing consideration?
A. Once-daily dosing without monitoring
B. Frequent therapeutic drug monitoring to maintain plasma concentrations within
therapeutic range [CORRECT]
C. Administration with food to enhance absorption
D. Dose reduction only in hepatic impairment
Correct Answer: B
Rationale: Correct because narrow therapeutic index drugs have minimal margin
between effective and toxic concentrations, necessitating routine monitoring of
plasma drug levels and clinical response.
Q5: Which receptor mechanism explains the action of beta-blockers on the heart?
A. Competitive antagonism of beta-1 adrenergic receptors [CORRECT]
B. Agonism at alpha-1 receptors
C. Noncompetitive antagonism at muscarinic receptors
D. Inverse agonism at dopamine receptors
Correct Answer: A
Rationale: Correct because beta-blockers competitively antagonize beta-1 adrenergic
receptors in cardiac tissue, reducing heart rate, contractility, and conduction velocity.
Q6: A patient with liver cirrhosis is prescribed a drug with high first-pass metabolism.
What is the expected effect?
A. Decreased bioavailability
B. Increased bioavailability and risk of toxicity [CORRECT]
C. No change in drug levels
D. Increased renal clearance
Correct Answer: B
Rationale: Correct because impaired hepatic first-pass metabolism reduces
presystemic drug extraction, increasing bioavailability and systemic exposure to
hepatotoxic drugs.
, Q7: Which pharmacodynamic term describes the maximum effect a drug can
produce?
A. Potency
B. Efficacy [CORRECT]
C. Affinity
D. Selectivity
Correct Answer: B
Rationale: Correct because efficacy refers to the maximal pharmacological response
achievable with a drug, regardless of the dose required to produce that effect.
Q8: A patient on digoxin has hypokalemia. Which pharmacodynamic interaction
increases digoxin toxicity risk?
A. Hypokalemia increases digoxin binding to Na+/K+-ATPase pumps [CORRECT]
B. Hypokalemia decreases digoxin absorption
C. Hypokalemia increases digoxin renal excretion
D. Hypokalemia antagonizes digoxin at receptor sites
Correct Answer: A
Rationale: Correct because hypokalemia increases digoxin binding to cardiac
Na+/K+-ATPase pumps, enhancing its inhibitory effect and increasing risk of
arrhythmias and toxicity.
Q9: Which route of administration bypasses first-pass metabolism?
A. Oral
B. Subcutaneous
C. Intravenous
D. Both B and C [CORRECT]
Correct Answer: D
Rationale: Correct because parenteral routes (subcutaneous, intravenous,
intramuscular) and transdermal administration bypass hepatic first-pass
metabolism, delivering drug directly to systemic circulation.
Q10: A drug with a half-life of 6 hours reaches steady-state concentration after
approximately:
A. 6 hours
B. 12 hours
C. 24-30 hours [CORRECT]
D. 48 hours
Correct Answer: C
Family Midterm Review Actual 2025/2026 with Detailed
Rationales | 100% Verified | Pass Guaranteed – A+
Graded
SECTION 1: Pharmacokinetics & Pharmacodynamics (15 questions)
Q1: A patient with renal impairment is prescribed a drug primarily eliminated by the
kidneys. Which pharmacokinetic parameter is most affected?
A. Absorption
B. Distribution
C. Metabolism
D. Elimination [CORRECT]
Correct Answer: D
Rationale: Correct because renal impairment primarily reduces drug elimination,
leading to accumulation and potential toxicity; dose adjustment is essential for
renally cleared medications.
Q2: A patient taking warfarin also starts phenytoin. The INR decreases. Which
pharmacokinetic interaction occurred?
A. Phenytoin inhibits warfarin absorption
B. Phenytoin induces hepatic cytochrome P450 enzymes, increasing warfarin
metabolism [CORRECT]
C. Phenytoin displaces warfarin from plasma proteins
D. Phenytoin decreases warfarin renal excretion
Correct Answer: B
Rationale: Correct because phenytoin is a potent CYP450 enzyme inducer that
accelerates warfarin metabolism, reducing its anticoagulant effect and requiring INR
monitoring with dose adjustment.
Q3: Which factor most increases the volume of distribution for lipophilic drugs?
A. Increased plasma protein binding
B. Decreased body fat
,C. Increased adipose tissue [CORRECT]
D. Decreased cardiac output
Correct Answer: C
Rationale: Correct because lipophilic drugs distribute extensively into adipose tissue;
increased body fat expands the apparent volume of distribution and may prolong
drug half-life.
Q4: A drug with a narrow therapeutic index requires which nursing consideration?
A. Once-daily dosing without monitoring
B. Frequent therapeutic drug monitoring to maintain plasma concentrations within
therapeutic range [CORRECT]
C. Administration with food to enhance absorption
D. Dose reduction only in hepatic impairment
Correct Answer: B
Rationale: Correct because narrow therapeutic index drugs have minimal margin
between effective and toxic concentrations, necessitating routine monitoring of
plasma drug levels and clinical response.
Q5: Which receptor mechanism explains the action of beta-blockers on the heart?
A. Competitive antagonism of beta-1 adrenergic receptors [CORRECT]
B. Agonism at alpha-1 receptors
C. Noncompetitive antagonism at muscarinic receptors
D. Inverse agonism at dopamine receptors
Correct Answer: A
Rationale: Correct because beta-blockers competitively antagonize beta-1 adrenergic
receptors in cardiac tissue, reducing heart rate, contractility, and conduction velocity.
Q6: A patient with liver cirrhosis is prescribed a drug with high first-pass metabolism.
What is the expected effect?
A. Decreased bioavailability
B. Increased bioavailability and risk of toxicity [CORRECT]
C. No change in drug levels
D. Increased renal clearance
Correct Answer: B
Rationale: Correct because impaired hepatic first-pass metabolism reduces
presystemic drug extraction, increasing bioavailability and systemic exposure to
hepatotoxic drugs.
, Q7: Which pharmacodynamic term describes the maximum effect a drug can
produce?
A. Potency
B. Efficacy [CORRECT]
C. Affinity
D. Selectivity
Correct Answer: B
Rationale: Correct because efficacy refers to the maximal pharmacological response
achievable with a drug, regardless of the dose required to produce that effect.
Q8: A patient on digoxin has hypokalemia. Which pharmacodynamic interaction
increases digoxin toxicity risk?
A. Hypokalemia increases digoxin binding to Na+/K+-ATPase pumps [CORRECT]
B. Hypokalemia decreases digoxin absorption
C. Hypokalemia increases digoxin renal excretion
D. Hypokalemia antagonizes digoxin at receptor sites
Correct Answer: A
Rationale: Correct because hypokalemia increases digoxin binding to cardiac
Na+/K+-ATPase pumps, enhancing its inhibitory effect and increasing risk of
arrhythmias and toxicity.
Q9: Which route of administration bypasses first-pass metabolism?
A. Oral
B. Subcutaneous
C. Intravenous
D. Both B and C [CORRECT]
Correct Answer: D
Rationale: Correct because parenteral routes (subcutaneous, intravenous,
intramuscular) and transdermal administration bypass hepatic first-pass
metabolism, delivering drug directly to systemic circulation.
Q10: A drug with a half-life of 6 hours reaches steady-state concentration after
approximately:
A. 6 hours
B. 12 hours
C. 24-30 hours [CORRECT]
D. 48 hours
Correct Answer: C
